Literature DB >> 22385927

Segmental bioimpedance for measuring amlodipine-induced pedal edema: a placebo-controlled study.

Dale A Schoeller1, Achilles Alon, Demetrios Manekas, Lori A Mixson, Kenneth C Lasseter, Gertrude P Noonan, James A Bolognese, Steven B Heymsfield, Chan R Beals, Irene Nunes.   

Abstract

BACKGROUND: The development of antihypertensives requires efficient and accurate tools for identifying pedal edema. Methodologies used to gauge the potential of an agent to induce pedal edema in short-term (<4-week) clinical trials have not been reported in the literature.
OBJECTIVE: The purpose of this study was to identify a robust and practical method for measuring drug-induced pedal edema for use in the clinical development of antihypertensives. The efficacy of segmental bioimpedance in the detection of increased pedal edema was compared with that of clinical pitting assessment, ankle circumference, and water displacement volumetry.
METHODS: The study population consisted of male and female healthy subjects and patients with stage 1 or 2 hypertension who were otherwise healthy. Participants were randomly assigned to receive amlodipine 10 mg or placebo once daily in this 6-week, double-blind, parallel-group study. Amlodipine was used as a means of inducing ankle edema, and not for the treatment of hypertension. Patients with hypertension were required to undergo a washout of antihypertensive therapies. Edema was evaluated using segmental bioimpedance at 10 kHz, clinical pitting assessment, ankle circumference, and water displacement at weeks 2, 4, and 6. The ANOVA model used included treatment and baseline values as covariates, with treatment pairs compared via t tests derived from the model.
RESULTS: A total of 47 individuals were randomized (49% male; 29 [62%] with hypertension; mean [SD] age, 59 [5.9] years; baseline body mass index, 28.6 kg/m(2) [2.8]; blood pressure 146.6 [10.7]/93.5 [6.5] and 139.3 [8.3]/89.5 [4.5] in individuals with and without hypertension, respectively; amlodipine 10 mg, n = 24; placebo, n = 23). At weeks 2, 4, and 6, statistically significant treatment differences in changes from baseline were detected using water displacement (mean [90% CI] treatment differences, +39.0 g [+17.9 to +60.1], +61.9 g [+36.1 to +87.6], and +72.2 g [+42.3 to +102.1], respectively; all, P ≤ 0.001), ankle circumference (+4.74 mm [+2.38 to +7.11; P < 0.001], +2.92 mm [+0.33 to +5.49; P = 0.032], and +5.16 mm [+2.21 to +8.11; P = 0.002]), and bioimpedance (-11.7 Ω [-18.1 to -5.4], -18.3 Ω [-26.2 to -10.4], and -20.9 Ω [-29.7 to -12.0]; all, P≤0.001), but no significant differences were detected using clinical assessment of pitting.
CONCLUSION: In this population of healthy subjects and patients with hypertension, segmental bioimpedance was comparable to water displacement and ankle circumference and outperformed clinical assessment of pitting for the detection of ankle edema, supporting the use of segmental bioimpedance as a drug-development tool to objectively quantify amlodipine-induced pedal edema. Copyright Â
© 2012 Elsevier HS Journals, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22385927     DOI: 10.1016/j.clinthera.2012.01.018

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  4 in total

1.  Prediction of hemodialysis vascular access failure using segmental bioimpedance analysis parameters.

Authors:  Hyunwoo Kim; Hye Mi Seo; Ji Young Kim; Miyeon Kim
Journal:  Int Urol Nephrol       Date:  2018-02-23       Impact factor: 2.370

2.  Leg edema quantification for heart failure patients via 3D imaging.

Authors:  Dieter Hayn; Friedrich Fruhwald; Arthur Riedel; Markus Falgenhauer; Günter Schreier
Journal:  Sensors (Basel)       Date:  2013-08-14       Impact factor: 3.576

3.  Overhydration measured by bioimpedance analysis and the survival of patients on maintenance hemodialysis: a single-center study.

Authors:  Ye Jin Kim; Hong Jae Jeon; Yoo Hyung Kim; Jaewoong Jeon; Young Rok Ham; Sarah Chung; Dae Eun Choi; Ki Ryang Na; Kang Wook Lee
Journal:  Kidney Res Clin Pract       Date:  2015-11-11

4.  A randomized phase 1b cross-over study of the safety of low-dose pioglitazone for treatment of autosomal dominant polycystic kidney disease.

Authors:  Bonnie L Blazer-Yost; Robert L Bacallao; Bradley J Erickson; Michelle L LaPradd; Marie E Edwards; Nehal Sheth; Kim Swinney; Kristen M Ponsler-Sipes; Ranjani N Moorthi; Susan M Perkins; Vicente E Torres; Sharon M Moe
Journal:  Clin Kidney J       Date:  2021-01-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.